. 2021 Apr;12(Suppl 1):S32–S44. doi: 10.21037/jgo-2020-04

Table 4. Therapeutic details focused on hyperthermic intraperitoneal chemotherapy (HIPEC) application.

Author	Year	Trial	Inclusion criteria	Total number of patients	cytotoxic drug	Dosage	Volume [liters]	Concentration [mg/L]	HIPEC duration [min]	HIPEC [°C]	HIPEC technique
Gastric cancer without peritoneal metastasis
Koga	1988	RCT	cT4	47	MMC	64–100 mg	10–12	6.4–10.0	50–60	42	closed
Kaibara	1989	RCT	cT4	82	MMC	n.a.	n.a.	n.a.	n.a.	n.a.	closed
Hamazoe	1994	RCT	cT4	82	MMC	10 mg/L	n.a.	10	50–60	40–42	closed
Ikeguchi	1995	RCT	cT3	174	MMC	80–100 mg/m²	8–10	12.8–20	n.a.	40–42	n.a.
Fujimoto^&	1999	RCT	cT4	141	MMC	10 mg/L	3–4	10	120	43–44	closed
Yonemura	2001	RCT	cT3-T4	95	CIS	300mg	6–8	37.5–50 *	n.a.	42–43	open
					MMC	30mg		3.75–5.0 *
Cui^&	2014	RCT	cT4	192	CIS^#	60 mg/m²	3	32	90	41–43	closed
					5-FU	0.75 g	3	250
Koga^&	1988	NRCT	cT4	93	MMC	64–100 mg	10–12	6.4–10.0	50–60	42
Yonemura	1995	NRCT	cT4	160	MMC	30 mg	8	3.75	60	41.5–43.5	open
					CIS	300 mg		37.5
Hirose^&	1999	NRCT	cT4	55	MMC	20 mg	4–5	4–5	50	41–44.5	open
					CIS	100 mg		20–25
					Etoposide	100 mg		20–25
Kunisaki	2002	NRCT	cT4	124	MMC	15 mg	5–6	2.5–3	40	42–43	open
					CIS	150 mg		25–30
					Etoposide	150 mg		25–30
Zhu^&	2006	NRCT	cT3-T4	118	MMC	5 mg/L	5–6	5	60	43±1.0	open
					CIS	50 mg/L		50
Kang^&	2013	NRCT	cT4	112	MMC	10 mg/L	3–4	10	60	41–43	closed
					CIS	30 mg/L		30
					Etoposide	20 mg/L		20
Gastric cancer with peritoneal metastasis
Yang^&	2011	RCT	PM	68	MMC	5 mg/L	6	5	60–90	43±0.5	open
					CIS	20 mg/L		20
Rudloff	2014	RCT	PM	17	Oxaliplatin	460 mg/m²	n.a.	n.a.	30	41	closed
Fujimoto^&	1997	NRCT	PM	66	MMC	10 mg/L	3–4	10	120	43–44	closed
Kunisaki	2006	NRCT	PM	73	MMC	30 mg	5–6	5–6	40	42–43	n.a.
					CIS	300 mg		50–60
					Etoposide	300 mg		50–60
Li^&	2010	NRCT	PM	54	MMC	5 mg/L	5–6	5	60	43.0±1.0	open
					CIS	50 mg/L		50
Zhibing	2013	NRCT	PM	101	CIS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Bonnot^&	2019	NRCT	PM	277	MMC⁺	30–50 mg/m²	n.a.	n.a.	60–120	41–43	Open or closed
					Irinotecan⁺	200 mg/m²			60–120	41–43
					CIS⁺	50–100 mg/m²			60–90	42–43
					DOX⁺	15 mg/m²			60–90	42–43
					Oxaliplatin⁺	300–460 mg/m²			30	43

^&, studies with significant survival benefit of HIPEC; *, calculated; ⁺, several combinations; ^#, on postoperative day 1 & 4. RCT, randomized controlled trial; NRCT, non-randomized controlled trial; CIS, cisplatin; PM, peritoneal metastasis; MMC, mitomycin C; n.a., not available; DOX, Doxorubicin;